Granulocyte stimulating factor (G-CSF)

Recombinant human serum albumin/granulocyte stimulating factor fusion protein for injection

READ MORE

Erythropoietin (EPO)

Recombinant human serum albumin/erythropoietin fusion protein for injection

READ MORE

Recombinant human serum albumin/granulocyte stimulating factor fusion protein

Streamlined production process, better stability and uniformity

READ MORE

Gene Recombinant Monoclonal Antibody Series Medical Injections

Used for the treatment of various diseases such as tumors and osteoporosis

READ MORE

Learn more about product information

Integrating the research and development, production, and sales of bio innovative drugs

READ MORE

TECHNICAL TEAM

Introduce international and domestic high-end pharmaceutical scientific research and other talents to promote the construction and operation of fuyuan Biotechnology Industrial Park

ABOUT

HUATONG FUYUAN BIOLOGY

Huatong Fuyuan Biopharmaceutical

A new type of pharmaceutical company integrating R&D, production and sales of bio-innovative drugs

Focus on the development of new projects in the field of biopharmaceuticals such as fusion proteins, monoclonal antibodies, and human vaccines, and gradually build Tai'an into a well-known biopharmaceutical research and development and production base in China, and build a biotechnology industry chain and industrial clusters.

Construction land 

130 acres

Total surface area

150,000 square meters

Total planned investment

3 billion yuan

NEWS

Mycobacterium tuberculosis fusion protein will be launched, and the tuberculosis industry chain is expected to open up a market space of 3.6 billion yuan
The EC, which has received the application for production registration this time, is at the front end of the tuberculosis industry chain, and can distinguish between BCG vaccination and tuberculosis infection in vivo diagnostic reagents for screening tuberculosis carriers. The 2017 WHO report showed that 10.4 million people worldwide suffer from tuberculosis, 1.8 million people died of tuberculosis in 2016, and 2 billion of the 7 billion people in the world have tuberculosis lurking in their bodies.
2021-12-27
Mycobacterium tuberculosis fusion protein will be launched, and the tuberculosis industry chain is expected to open up a market space of 3.6 billion yuan

Communication, start here

SUBMIT